Business Wire

BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report

22.1.2025 10:00:00 EET | Business Wire | Press release

Share

BON CHARGE, a global leader in premium wellness technology, today announces the release of its inaugural Global Red Light Therapy Trend Report, showcasing how red light therapy is fast becoming a cornerstone of modern wellness routines. Based on a global survey of 7,000 adults across the U.S., UK, UAE, and Australia, the report highlights the rising adoption of red light therapy, particularly among younger consumers, with the UAE leading with seven in ten adults actively using red light therapy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122177591/en/

BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report (Photo: Business Wire)

Coinciding with the release, BON CHARGE debuts its brand refresh, including a redesigned website. This emphasizes BON CHARGE’s mission to simplify wellness by offering the world’s widest range of wellness products on a single, easy-to-access platform, empowering individuals to prioritize their self-care with science-backed technology solutions.

“As consumers become increasingly interested in their overall wellness, they are searching for accessible tools that offer multiple benefits, making red light therapy a game-changer,” said Katie Mant, Co-Founder of BON CHARGE. “Our research underscores its impact on key areas like skin appearance, sleep, and recovery, showcasing its role in shaping the future of proactive wellness worldwide.”

Red Light Therapy: A Global Trend in Wellness

The BON CHARGE Global Red Light Therapy Trend Report provides key insights into how this emerging technology is reshaping global wellness routines:

  • UAE Leading the Way: Red light therapy has gained remarkable traction in the UAE, where 70% of adults report using it—far exceeding adoption rates in other markets. Nearly a third (30%) use it monthly, underscoring its popularity as a regular wellness practice.
  • Younger Generations Drive Adoption: Across all surveyed markets, adults aged 18-34 are the most engaged users of red light therapy, with standout adoption rates of 77% in the UAE, 53% in the U.S. and Australia, and 46% in the UK.
  • A Recent Addition to Wellness Routines: Red light therapy is still a relatively new addition for many users, with two-thirds globally reporting they started in the past two years. Younger adults (18-34) are driving this trend, with 73% of users in the UK, 70% in the UAE and 71% in the U.S. and Australia having adopted the practice recently.
  • Top Device of Choice: Red light face masks lead globally as the most popular device, chosen by around a third of users (35% in the UAE, 34% in Australia, 36% in the UK and 27% in the U.S.). Note: Preferences vary by region with devices to soothe joint stiffness taking the lead in the UK and U.S. (38% and 30%, respectively).

Regional Insights Reflect Diverse Motivations

Red light therapy is a growing phenomenon. While muscle and joint relaxation is the top reason for use globally, regional nuances reveal additional motivations behind its widespread appeal:

  • United Arab Emirates: The UAE sets the pace for global adoption with nearly 70% of adults engaged with red light therapy. A greater understanding of red light therapy and professional endorsements drive this trend, with 37% of users recommended by a skin specialist.
  • Australia: Australians cite sleep improvement and skincare benefits as key reasons for use, after muscle and joint relaxation, and well over half (61%) have adopted red light therapy within the past two years.
  • United States: Adoption is stronger among men than women in the United States, with nearly 40% reporting usage. Improved sleep and mood are cited as key motivators (28% and 24%, respectively) by users, highlighting the growing focus on recovery and mental well-being.
  • United Kingdom: While adoption lags behind other markets, red light therapy is rapidly gaining traction among younger adults, with 73% of users aged 18-34 starting in the last two years. With lead motivation for use being skincare benefits, following muscle and joint relaxation.

“This report reflects a global movement toward proactive wellness,” said Andy Mant, Co-Founder of BON CHARGE. “Red light therapy’s rapid adoption, particularly among younger generations, signals a significant shift. As science continues to validate its benefits, we believe it will become as essential to wellness as nutrition and fitness.”

Explore the Full Report and Press Kit
Access the BON CHARGE Global Red Light Therapy Global Trend Report and explore key findings, visual assets, and additional resources in our digital press kit. Visit boncharge.com to download the report and learn more about BON CHARGE’s pioneering wellness solutions.

Notes to Editors
Research of 7,000 adults across the UK, USA, UAE, and Australia by Opinium Research in December 2024.

About BON CHARGE
Founded in 2017 by Katie and Andy Mant, BON CHARGE is setting new standards in simplifying wellness by offering the widest range of science-backed technology solutions to help individuals navigate their wellness journeys. The brand celebrates wellness as a continuous journey, honoring individuality and inspiring growth through community and shared knowledge. From sleep and recovery to beauty and mental well-being, BON CHARGE is a trusted partner in proactive self-care. Headquartered in Perth, Australia, every product is rooted in rigorous scientific research and designed to help individuals in achieving their wellness goals. For more information, visit boncharge.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250122177591/en/

Contacts

Press Contact
Jack Taylor PR
boncharge@jacktaylorpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release

A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye